Urology
Volume 72, Issue 6, Supplement , Pages S36-S43 , December 2008

New Treatments for Localized Prostate Cancer

  • Michael Marberger

      Affiliations

    • Department of Urology, Medical University of Vienna, Vienna, Austria
    • Corresponding Author InformationReprint requests: Michael Marberger, M.D., Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna A-1090 Austria
    • ,
  • Peter R. Carroll

      Affiliations

    • University of California, San Francisco, San Francisco, California
    • ,
  • Michael J. Zelefsky

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Jonathan A. Coleman
    • ,
  • Hedvig Hricak

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Peter T. Scardino

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Lucien L. Abenhaim

      Affiliations

    • McGill University, Montreal, Canada

References 

  1. Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol. 2007;178:2260–2267
  2. Shinohara K. Thermal ablation of prostate diseases: advantages and limitations. Int J Hyperthermia. 2004;20:679–697
  3. Shinohara K. Prostate cancer: cryotherapy. Urol Clin North Am. 2003;30:725–736viii
  4. Prepelica KL, Okeke Z, Murphy A, et al. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer. 2005;103:1625–1630
  5. Long JP, Bahn D, Lee F, et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology. 2001;57:518–523
  6. Koppie TM, Shinohara K, Grossfeld GD, et al. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. J Urol. 1999;162:427–432
  7. Shinohara K, Rhee B, Presti JC, et al. Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol. 1997;158:2206–2210
  8. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–523
  9. Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171:1520–1524
  10. Onik G. The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation: a review. Technol Cancer Res Treat. 2004;3:365–370
  11. Anastasiadis AG, Sachdev R, Salomon L, et al. Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. J Cancer Res Clin Oncol. 2003;129:676–682
  12. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80
  13. Thompson I, Thrasher JB, Aus G, et al. Prostate Cancer: Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. Linthicum, MD: American Urological Association Education and Research, Inc; 2007;http://www.auanet.org/guidelines/main_reports/proscan07/content.pdfAccessed January 22, 2008
  14. Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer. 2005;5:321–327
  15. Madersbacher S, Pedevilla M, Vingers L, et al. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 1995;55:3346–3351
  16. Chapelon JY, Margonari J, Vernier F, et al. In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma dunning R3327. Cancer Res. 1992;52:6353–6357
  17. Yang R, Reilly CR, Rescorla FJ, et al. High-intensity focused ultrasound in the treatment of experimental liver cancer. Arch Surg. 1991;126:1002–1010
  18. Oosterhof GO, Cornel EB, Smits GA, et al. Influence of high-intensity focused ultrasound on the development of metastases. Eur Urol. 1997;32:91–95
  19. Madersbacher S, Marberger M. High-energy shockwaves and extracorporeal high-intensity focused ultrasound. J Endourol. 2003;17:667–672
  20. Gelet A, Chapelon JY. Effects of high-intensity focused ultrasound on malignant cells and tissues. In:  Marberger M editors. Application of Newer Forms of Therapeutic Energy in Urology. Oxford: Isis Medical Media; 1995;p. 107–114
  21. Chaussy G, Thüroff S, Kiel HJ. High intensity focused ultrasound (HIFU) and neoadjuvant transurethral resection. Eur Urol Suppl. 2003;2:135
  22. Vallancien G, Prapotnich D, Cathelineau X, et al. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol. 2004;171:2265–2267
  23. Chauhan S, Lowe MJ, Davies BL. A multiple focused probe approach for high intensity focused ultrasound based surgery. Ultrasonics. 2001;39:33–44
  24. Sokka SD, Hynynen KH. The feasibility of MRI-guided whole prostate ablation with a linear aperiodic intracavitary ultrasound phased array. Phys Med Biol. 2000;45:3373–3383
  25. Thüroff S, Chaussy C, Vallancien G, et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol. 2003;17:673–677
  26. Thüroff S, Kiel HJ, Knauer K, et al. High intensity focused ultrasound (HIFU) in prostate cancer—side effects after 1000 treatments in 8 years. Eur Urol Suppl. 2005;4:82
  27. Gelet A, Chapelon JY, Poissonier L, et al. Prostate cancer control with transrectal HIFU in 242 consecutive patients: 5-year results. Eur Urol Suppl. 2004;3:214
  28. Blana A, Murat FJ, Walter B, et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol. 2008;53:1194–2001
  29. Uchida T, Ohkusa H, Yamashita A, et al. High-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer using Sonablate-500. In:  Ter Haar GR,  Rivens I editor. Fourth ISTU Symposium. Melville, NY: American Institute of Physics; 2005;p. 3–63
  30. Chen W, Carlos R, Fedewa R, et al. The detection and exclusion of the prostate neurovascular bundle (NVB) in automated HIFU treatment planning using a pulsed-wave Doppler ultrasound system. In:  Ter Haar GR,  Rivens I editor. Fourth ISTU Symposium. Melville, NY: American Institute of Physics; 2005;p. 23–263
  31. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004;5:497–508
  32. Vogl TJ, Eichler K, Mack MG, et al. Interstitial photodynamic laser therapy in interventional oncology. Eur Radiol. 2004;14:1063–1073
  33. Martin NE, Hahn SM. Interstitial photodynamic therapy for prostate cancer: a developing modality. Photodiagn Photodyn Ther. 2004;1:123–136
  34. Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem. 2004;47:3897–3915
  35. Muschter R. Photodynamic therapy: a new approach to prostate cancer. Curr Urol Rep. 2003;4:221–228
  36. Salomon Y, Gross S, Gilead A, et al. Eradication of melanoma tumors by anti vascular photodynamic therapy (PDT) with TOOKAD, a pd-bacteriochlorophyll derivative: if you can't fight them, starve them. Presented at the 18th International Pigment Cell Conference, September 9-13, 2002, Egmond aan Zee, The Netherlands.
  37. Vakrat-Haglili Y, Weiner L, Brumfeld V, et al. The microenvironment effect on the generation of reactive oxygen species by Pd-bacteriopheophorbide. J Am Chem Soc. 2005;127:6487–6497
  38. Borle F, Radu A, Fontolliet C, et al. Selectivity of the photosensitiser TOOKAD for photodynamic therapy evaluated in the Syrian golden hamster cheek pouch tumour model. Br J Cancer. 2003;89:2320–2326
  39. Garbo GM, KiK PK, Harrison LT, et al. Differential vascular response and relationship to tumor response with photodynamic therapy using WST-09 (TOOKAD). In:  Kessel D editors. Proceedings of SPIE (5315). Bellingham, WA: International Society for Optical Engineering; 2004;p. 18–26
  40. Huang Z, Chen Q, Luck D, et al. Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer. Lasers Surg Med. 2005;36:390–397
  41. Hetzel FW, Chen Q, Luck D, et al. Preclinical studies of vascular acting photosensitizer bacteriopheophorbide for the treatment of prostate cancer. In:  Kessel D editors. Proceedings of SPIE (5315). Bellingham, WA: International Society for Optical Engineering; 2004;p. 27–32
  42. Trachtenberg J, Bogaards A, Haider M, et al. Vascular targeted photodynamic with WST09 (WST09-VTP) for locally recurrent prostate cancer following radiation therapy. BJU Int. 2004;94(suppl 2):57
  43. Trachtenberg J, Bozaards A, Weersink RA, et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol. 2007;178(5):1974–1979
  44. Schreiber S, Gross S, Brandis A, et al. Local photodynamic therapy (PDT) of rat C6 glioma xenografts with Pd-bacteriopheophorbide leads to decreased metastases and increase of animal cure compared with surgery. Int J Cancer. 2002;99:279–285
  45. Koudinova NV, Pinthus JH, Brandis A, et al. Photodynamic therapy with Pd-bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer. 2003;104:782–789
  46. Kelleher DK, Thews O, Scherz A, et al. Perfusion, oxygenation status and growth of experimental tumors upon photodynamic therapy with Pd-bacteriopheophorbide. Int J Oncol. 2004;24:1505–1511
  47. Plaks V, Koudinova N, Nevo U, et al. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. Neoplasia. 2004;6:224–233
  48. Woodhams JH, MacRobert AJ, Novelli M, et al. Photodynamic therapy with WST09 (Tookad): quantitative studies in normal colon and transplanted tumours. Int J Cancer. 2006;118:477–482
  49. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res. 2001;21:4271–4277
  50. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380–387
  51. Weersink RA, Wilson BC, Patterson MS. Determination of the peak absorption wavelength and disaggregation kinetics of TOOKAD in vivo using dynamic, spatially resolved diffuse reflectance spectroscopy in a rabbit model. In:  Alfano RR editors. Proceedings of SPIE (5315). Bellingham, WA: International Society for Optical Engineering; 2002;p. 135–142
  52. Gross S, Gilead A, Scherz A, et al. Monitoring photodynamic therapy of solid tumors online by bold-contrast MRI. Nat Med. 2003;9:1327–1331
  53. Chen Q, Huang Z, Luck D, et al. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Photochem Photobiol. 2002;76:438–445
  54. Chen Q, Huang Z, Luck D, et al. Effects of TOOKAD-PDT on canine prostates pre-treated with ionizing radiation. In:  Kessel D editors. Proceedings of SPIE (4952). Bellingham, WA: International Society for Optical Engineering; 2003;p. 115–124
  55. Huang Z, Chen Q, Brun PH, et al. Studies of a novel photosensitizer Pd-bacteriopheophorbide (Tookad) for the prostate cancer PDT in canine model. In:  Hwu J editors. Proceedings of SPIE (5254) 2003. Bellingham, WA: International Society for Optical Engineering; 2004;p. 83–90
  56. Huang Z, Chen Q, Trncic N, et al. Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation. Radiat Res. 2004;161:723–731
  57. Huang Z, Haider MA, Kraft S, et al. Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland. Lasers Surg Med. 2006;38:672–681
  58. Huang Z, Chen Q, Dole KC, et al. The effect of Tookad-mediated photodynamic ablation of the prostate gland on adjacent tissues—in vivo study in a canine model. Photochem Photobiol Sci. 2007;6:1318–1324
  59. Trachtenberg J, Weersink RA, Davidson SR, et al. Vascular-targeted photodynamic therapy (Padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008;102(5):556–562
  60. Pinthus JH, Bogaards A, Weersink R, et al. Photodynamic therapy for urological malignancies: past to current approaches. J Urol. 2006;175:1201–1207
  61. Weersink RA, Wilson B, Bogaards A, et al. Vascular-targeted photodynamic of prostate cancer with Tookad for recurrent prostate cancer following radiation therapy: initial clinical studies. In:  Kessel D editors. Proceedings of SPIE (6424). Bellingham, WA: International Society for Optical Engineering; 2007;p. 1–10
  62. Trachtenberg J, Bogaards A, Weersink RA, et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol. 2007;178:1974–1979
  63. Haider MA, Davidson SR, Kale AV, et al. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology. 2007;244:196–204
  64. Trachtenberg J, Weersink RA, Davidson SRH, et al. TOOKAD (Padoporfin, WST09) for recurrent prostate cancer after EBRT failure: a light-dose escalating study. BJU Int. 2008;Epub May 19
  65. Moore C, Hoh I, Mosse CA, et al. Vascular-targeted photodynamic therapy in organ-confined prostate cancer—report of a novel photosensitiser. Eur Urol Suppl. 2006;5:131
  66. Pendse D, Allen C, Moore C, et al. Dynamic contrast-enhanced magnetic resonance imaging after vascular targeted photodynamic therapy with TOOKAD in the primary treatment of prostate cancer. Presented at the Annual Meeting of the American Urological Association (AUA), May 19-24, 2007, Anaheim, CA, Poster presentation 1694.
  67. Brun PH, Bucking M, DeGroot JL, et al. Neutron activation and liquid scintillation analysis of tissue samples containing palladium bacteriochlorophyll derivative, a potential photochemotherapeutic agent. Can J Anal Sci Spectrosc. 2004;49:55–63
  68. Weersink RA, Forbes J, Bisland S, et al. Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients. Photochem Photobiol. 2005;81:106–113

PII: S0090-4295(08)01609-9

doi: 10.1016/j.urology.2008.08.506

Urology
Volume 72, Issue 6, Supplement , Pages S36-S43 , December 2008

Article Tools